An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
NCT02531126
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
877
Enrollment
INDUSTRY
Sponsor class
Conditions
Ulcerative Colitis
Interventions
DRUG:
RPC1063
Sponsor
Celgene